Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 2/3 2Phase 1 2Phase 4 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Dermatologic 1

Conditions

Recurrence 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cytarabine 25Cyclophosphamide 23venetoclax 16Methotrexate 15Daunorubicin 14Dexamethasone 13Vincristine 11Etoposide 11Azacitidine 10Idarubicin 9Decitabine 9Busulfan 9fludarabine 8Radiotherapy 8Prednisone 8Stem Cell Transplantation 7Mercaptopurine 7Doxorubicin 7Asparaginase 7pegaspargase 6fludarabine phosphate 6blinatumomab 6Granulocyte Colony-Stimulating Factor 6Gemtuzumab 6Filgrastim 6Thiotepa 5Methylprednisolone 5Dasatinib 5Whole-Body Irradiation 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × peginterferon alfa-2b × Other hematologic neoplasm × Clear all
NCT02634294 2023-03-16

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Completed
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Recurrence, Hematologic Neoplasms

NCT03547154 2019-08-12

C98026

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
344 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡